Acidic cannabinoids like THCA and CBDA show unique therapeutic potential but face major hurdles getting to clinical use

Acidic cannabinoids show unique biological activities distinct from their neutral counterparts, including neuroprotective, anti-inflammatory, anticonvulsant, and anti-proliferative effects mediated through 5-HT1A receptors, COX-2, TRP channels, and PPARgamma. They are non-intoxicating in unheated form, making them potentially suitable for children and elderly patients.

Systematic narrative review of peer-reviewed literature from major scientific databases focusing on acidic cannabinoid chemistry, pharmacology, pharmacokinetics, and disease-specific applications.

Most cannabis research focuses on THC and CBD, their neutral (decarboxylated) forms. The acidic precursors THCA and CBDA are what the plant actually produces, and they appear to have their own therapeutic profiles that are only beginning to be understood.

Raw cannabis consumption and low-temperature preparations preserve acidic cannabinoids. As interest grows in precision cannabinoid medicine, understanding these compounds could open entirely new therapeutic categories distinct from traditional THC/CBD applications.

Narrative review without systematic methodology for study selection. Most evidence is preclinical. Chemical instability of acidic cannabinoids poses challenges for drug development. The non-intoxicating claim applies only to non-heated consumption; heating converts THCA to psychoactive THC.